{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:51:04Z","timestamp":1790891464549,"version":"4.1.0"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"17-18","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s10354-006-0330-5","type":"journal-article","created":{"date-parts":[[2006,10,17]],"date-time":"2006-10-17T19:36:11Z","timestamp":1161113771000},"page":"472-480","source":"Crossref","is-referenced-by-count":8,"title":["Current developments in anti-platelet therapy","Aktuelle Entwicklungen in der Thrombozytenfunktonshemmung"],"prefix":"10.1007","volume":"156","author":[{"given":"Florian B.","family":"Mayr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"330_CR1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJM199405053301808","volume":"330","author":"C Patrono","year":"1994","unstructured":"Patrono C (1994) Aspirin as an antiplatelet drug. N Engl J Med 330: 1287\u20131294","journal-title":"N Engl J Med"},{"key":"330_CR2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0735-1097(98)00601-9","volume":"33","author":"JD Folts","year":"1999","unstructured":"Folts JD, Schafer AI, Loscalzo J, Willerson JT, Muller JE (1999) A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. J Am Coll Cardiol 33: 295\u2013303","journal-title":"J Am Coll Cardiol"},{"key":"330_CR3","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1161\/01.CIR.93.6.1201","volume":"93","author":"N Maalej","year":"1996","unstructured":"Maalej N, Folts JD (1996) Increased shear stress overcomes the antithrombotic platelet inhibitory effect of aspirin in stenosed dog coronary arteries. Circulation 93: 1201\u20131205","journal-title":"Circulation"},{"key":"330_CR4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.V82.2.505.505","volume":"82","author":"CS Rinder","year":"1993","unstructured":"Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR (1993) Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release. Blood 82: 505\u2013512","journal-title":"Blood"},{"key":"330_CR5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1042\/cs0870575","volume":"87","author":"NA Chronos","year":"1994","unstructured":"Chronos NA, Wilson DJ, Janes SL, Hutton RA, Buller NP, Goodall AH (1994) Aspirin does not affect the flow cytometric detection of fibrinogen binding to, or release of alpha-granules or lysosomes from, human platelets. Clin Sci (Lond) 87: 575\u2013580","journal-title":"Clin Sci (Lond)"},{"key":"330_CR6","doi-asserted-by":"crossref","unstructured":"Lloyd J (1996) Aspirin: how low is low dose? Aust Prescriber 79\u201381","DOI":"10.18773\/austprescr.1996.070"},{"key":"330_CR7","first-page":"38","volume":"75","author":"LL Craven","year":"1953","unstructured":"Craven LL (1953) Experiences with aspirin (Acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J 75: 38\u201344","journal-title":"Miss Valley Med J"},{"key":"330_CR8","first-page":"349","volume":"2","author":"The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","year":"1988","unstructured":"The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2: 349\u2013360","journal-title":"Lancet"},{"key":"330_CR9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/bmj.308.6923.235","volume":"308","author":"The Antiplatelet Trialists' Collaboration","year":"1994","unstructured":"The Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy \u2013III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 308: 235\u2013246","journal-title":"BMJ"},{"key":"330_CR10","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1136\/bmj.316.7141.1337","volume":"316","author":"C Baigent","year":"1998","unstructured":"Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R (1998) ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. BMJ 316: 1337\u20131343","journal-title":"BMJ"},{"issue":"7329","key":"330_CR11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"The Antithrombotic Trialists' Collaboration","year":"2002","unstructured":"The Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329): 71\u201386","journal-title":"BMJ"},{"key":"330_CR12","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0140-6736(89)90613-2","volume":"2","author":"X Carne","year":"1989","unstructured":"Carne X, Arnau JM, Laporte JR (1989) Aspirin, ticlopidine, and stroke. Lancet 2: 442\u2013443","journal-title":"Lancet"},{"key":"330_CR13","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1161\/01.STR.23.10.1395","volume":"23","author":"ML Dyken","year":"1992","unstructured":"Dyken ML, Barnett HJ, Easton JD, Fields WS, Fuster V, Hachinski V, Norris JW, Sherman DG (1992) Low-dose aspirin and stroke. \"It ain't necessarily so\". Stroke 23: 1395\u20131399","journal-title":"Stroke"},{"key":"330_CR14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7326\/0003-4819-121-1-199407010-00008","volume":"121","author":"DB Matchar","year":"1994","unstructured":"Matchar DB, McCrory DC, Barnett HJ, Feussner JR (1994) Medical treatment for stroke prevention. Ann Intern Med 121: 41\u201353","journal-title":"Ann Intern Med"},{"key":"330_CR15","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","volume":"349","author":"The CAST (Chinese Acute Stroke Trial) Collaborative Group","year":"1997","unstructured":"The CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349: 1641\u20131649","journal-title":"Lancet"},{"key":"330_CR16","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(97)04011-7","volume":"349","author":"The International Stroke Trial Collaborative Group","year":"1997","unstructured":"The International Stroke Trial Collaborative Group (1997) The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 349: 1569\u20131581","journal-title":"Lancet"},{"key":"330_CR17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-136-2-200201150-00016","volume":"136","author":"M Hayden","year":"2002","unstructured":"Hayden M, Pignone M, Phillips C, Mulrow C (2002) Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U. S. Preventive Services Task Force. Ann Intern Med 136: 161\u2013172","journal-title":"Ann Intern Med"},{"key":"330_CR18","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/archinte.163.17.2006","volume":"163","author":"RS Eidelman","year":"2003","unstructured":"Eidelman RS, Hebert PR, Weisman SM, Hennekens CH (2003) An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 163: 2006\u20132010","journal-title":"Arch Intern Med"},{"key":"330_CR19","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352: 1293\u20131304","journal-title":"N Engl J Med"},{"key":"330_CR20","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMcp012672","volume":"346","author":"MS Lauer","year":"2002","unstructured":"Lauer MS (2002) Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 346: 1468\u20131474","journal-title":"N Engl J Med"},{"key":"330_CR21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0735-1097(02)02006-5","volume":"40","author":"SP Marso","year":"2002","unstructured":"Marso SP (2002) Optimizing the diabetic formulary: beyond aspirin and insulin. J Am Coll Cardiol 40: 652\u2013661","journal-title":"J Am Coll Cardiol"},{"key":"330_CR22","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.CIR.101.10.1206","volume":"101","author":"EH Awtry","year":"2000","unstructured":"Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101: 1206\u20131218","journal-title":"Circulation"},{"key":"330_CR23","first-page":"691","volume":"8","author":"CH Hennekens","year":"2002","unstructured":"Hennekens CH (2002) Update on aspirin in the treatment and prevention of cardiovascular disease. Am J Manag Care 8: 691\u2013700","journal-title":"Am J Manag Care"},{"key":"330_CR24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0002-8703(95)90353-4","volume":"130","author":"M Buerke","year":"1995","unstructured":"Buerke M, Pittroff W, Meyer J, Darius H (1995) Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 130: 465\u2013472","journal-title":"Am Heart J"},{"key":"330_CR25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.STR.0000064841.47697.22","volume":"34","author":"HP Adams Jr","year":"2003","unstructured":"Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ (2003) Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke 34: 1056\u20131083","journal-title":"Stroke"},{"key":"330_CR26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1378\/chest.126.3_suppl.513S","volume":"126","author":"RA Harrington","year":"2004","unstructured":"Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer DA, Guyatt GH (2004) Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 513\u2013548","journal-title":"Chest"},{"key":"330_CR27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-136-2-200201150-00015","volume":"136","author":"US Preventive Services Task Force","year":"2002","unstructured":"US Preventive Services Task Force (2002) Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 136: 157\u2013160","journal-title":"Ann Intern Med"},{"key":"330_CR28","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/01.CIR.0000020190.45892.75","volume":"106","author":"TA Pearson","year":"2002","unstructured":"Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA (2002) AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106: 388\u2013391","journal-title":"Circulation"},{"key":"330_CR29","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1046\/j.1538-7836.2003.00284.x","volume":"1","author":"C Patrono","year":"2003","unstructured":"Patrono C (2003) Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 1: 1710\u20131713","journal-title":"J Thromb Haemost"},{"key":"330_CR30","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1161\/01.ATV.0000145980.39477.a9","volume":"24","author":"M Cattaneo","year":"2004","unstructured":"Cattaneo M (2004) Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24: 1980\u20131987","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"330_CR31","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","volume":"105","author":"JW Eikelboom","year":"2002","unstructured":"Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002) Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650\u20131655","journal-title":"Circulation"},{"key":"330_CR32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1067\/mlc.2001.117406","volume":"138","author":"B Jilma","year":"2001","unstructured":"Jilma B (2001) Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 138: 152\u2013163","journal-title":"J Lab Clin Med"},{"key":"330_CR33","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/01.CIR.0000141575.92958.9C","volume":"110","author":"M Frossard","year":"2004","unstructured":"Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B (2004) Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110: 1392\u20131397","journal-title":"Circulation"},{"key":"330_CR34","unstructured":"Jilma B, Fuchs I, Spiel A, Laggner A, Frossard M (2005) Platelet hyperfunction and low response to aspirin predict re-events in patients with acute coronary syndromes during long-term follow-up. Circulation 112: II-690: 3233"},{"key":"330_CR35","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/69537100412351272550","volume":"15","author":"A Sambola","year":"2004","unstructured":"Sambola A, Heras M, Escolar G, Lozano M, Pino M, Martorell T, Torra M, Sanz G (2004) The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin. Platelets 15: 439\u2013446","journal-title":"Platelets"},{"key":"330_CR36","unstructured":"Gianetti J, Parri MS, Sbrana S, Paoli F, Maffei S, Paradossi U, Berti S, Clerico A, Biagini A (2005) Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: A 6 months prospective study. Thromb Res in press, DOI 10.1016"},{"key":"330_CR37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/0953710021000057866","volume":"13","author":"S Ziegler","year":"2002","unstructured":"Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E (2002) Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 13: 493\u2013497","journal-title":"Platelets"},{"key":"330_CR38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(02)07370-1","volume":"359","author":"WA Ray","year":"2002","unstructured":"Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR (2002) Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359: 118\u2013123","journal-title":"Lancet"},{"key":"330_CR39","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/archinte.162.10.1111","volume":"162","author":"E Rahme","year":"2002","unstructured":"Rahme E, Pilote L, LeLorier J (2002) Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 162: 1111\u20131115","journal-title":"Arch Intern Med"},{"key":"330_CR40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00001648-200007000-00004","volume":"11","author":"LA Garcia Rodriguez","year":"2000","unstructured":"Garcia Rodriguez LA, Varas C, Patrono C (2000) Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 11: 382\u2013387","journal-title":"Epidemiology"},{"key":"330_CR41","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0140-6736(02)09350-9","volume":"360","author":"DH Solomon","year":"2002","unstructured":"Solomon DH, Glynn RJ, Avorn J (2002) Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360: 90","journal-title":"Lancet"},{"key":"330_CR42","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/j.jacc.2004.07.014","volume":"44","author":"EM Antman","year":"2004","unstructured":"Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK (2004) ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 44: E1\u2013E211","journal-title":"J Am Coll Cardiol"},{"key":"330_CR43","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","volume":"361","author":"TM MacDonald","year":"2003","unstructured":"MacDonald TM, Wei L (2003) Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361: 573\u2013574","journal-title":"Lancet"},{"key":"330_CR44","first-page":"229","volume":"21","author":"M Homoncik","year":"2003","unstructured":"Homoncik M, Malec M, Marsik C, Sycha T, Anzenhofer S, Gustorff B, Jilma B (2003) Rofecoxib exerts no effect on platelet plug formation in healthy volunteers. Clin Exp Rheumatol 21: 229\u2013231","journal-title":"Clin Exp Rheumatol"},{"key":"330_CR45","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","volume":"352","author":"RS Bresalier","year":"2005","unstructured":"Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092\u20131102","journal-title":"N Engl J Med"},{"key":"330_CR46","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071\u20131080","journal-title":"N Engl J Med"},{"key":"330_CR47","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","volume":"352","author":"NA Nussmeier","year":"2005","unstructured":"Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081\u20131091","journal-title":"N Engl J Med"},{"key":"330_CR48","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/01.CIR.0000160005.90598.41","volume":"111","author":"JS Bennett","year":"2005","unstructured":"Bennett JS, Daugherty A, Herrington D, Greenland P, Roberts H, Taubert KA (2005) The use of nonsteroidal anti-inflammatory drugs (NSAIDs): a science advisory from the American Heart Association. Circulation 111: 1713\u20131716","journal-title":"Circulation"},{"key":"330_CR49","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1378\/chest.119.1_suppl.39S","volume":"119","author":"C Patrono","year":"2001","unstructured":"Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G (2001) Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest 119: 39S\u201363S","journal-title":"Chest"},{"key":"330_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","volume":"143","author":"HC Diener","year":"1996","unstructured":"Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996) European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143: 1\u201313","journal-title":"J Neurol Sci"},{"key":"330_CR51","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1161\/01.STR.0000082381.23938.0E","volume":"34","author":"EL De Schryver","year":"2003","unstructured":"De Schryver EL, Algra A, van Gijn J (2003) Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 34: 2072\u20132080","journal-title":"Stroke"},{"key":"330_CR52","first-page":"96","volume":"145","author":"PRoFESS study presented","year":"2003","unstructured":"PRoFESS study presented (2003) Change in secondary prevention. MMW Fortschr Med 145: 96\u201397","journal-title":"MMW Fortschr Med"},{"key":"330_CR53","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1586\/14779072.1.4.611","volume":"1","author":"M Moonis","year":"2003","unstructured":"Moonis M, Fisher M (2003) Antiplatelet treatment for secondary prevention of acute ischemic stroke and transient ischemic attacks: mechanisms, choices and possible emerging patterns of use. Expert Rev Cardiovasc Ther 1: 611\u2013615","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"330_CR54","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.STR.0000023120.91460.F3","volume":"33","author":"C Warlow","year":"2002","unstructured":"Warlow C (2002) Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke. Stroke 33: 2137\u20132138","journal-title":"Stroke"},{"key":"330_CR55","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1254\/jjp.82.188","volume":"82","author":"H Hirose","year":"2000","unstructured":"Hirose H, Kimura T, Okada M, Itoh Y, Ishida F, Mochizuki N, Nishibe T, Nishikibe M (2000) Antiplatelet and antithrombotic effects of a novel selective phosphodiesterase 3 inhibitor, NSP-513, in mice and rats. Jpn J Pharmacol 82: 188\u2013198","journal-title":"Jpn J Pharmacol"},{"key":"330_CR56","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejphar.2003.10.046","volume":"483","author":"CC Wu","year":"2004","unstructured":"Wu CC, Wang WY, Kuo RY, Chang FR, Wu YC (2004) Antiplatelet effects of KW-7, a new inhibitor of cyclic nucleotide phosphodiesterases. Eur J Pharmacol 483: 187\u2013194","journal-title":"Eur J Pharmacol"},{"key":"330_CR57","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0165-6147(98)01248-6","volume":"19","author":"SP Kunapuli","year":"1998","unstructured":"Kunapuli SP (1998) Multiple P2 receptor subtypes on platelets: a new interpretation of their function. Trends Pharmacol Sci 19: 391\u2013394","journal-title":"Trends Pharmacol Sci"},{"key":"330_CR58","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1046\/j.1365-2141.1998.01056.x","volume":"103","author":"B Hechler","year":"1998","unstructured":"Hechler B, Eckly A, Ohlmann P, Cazenave JP, Gachet C (1998) The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 103: 858\u2013866","journal-title":"Br J Haematol"},{"key":"330_CR59","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.ATV.19.8.2007","volume":"19","author":"J Geiger","year":"1999","unstructured":"Geiger J, Brich J, Honig-Liedl P, Eigenthaler M, Schanzenbacher P, Herbert JM, Walter U (1999) Specific impairment of human platelet P2Y(AC) ADP receptormediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 19: 2007\u20132011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"330_CR60","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"The CAPRIE Steering Committee","year":"1996","unstructured":"The CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329\u20131339","journal-title":"Lancet"},{"key":"330_CR61","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198908243210804","volume":"321","author":"WK Hass","year":"1989","unstructured":"Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B (1989) A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 321: 501\u2013507","journal-title":"N Engl J Med"},{"key":"330_CR62","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2165\/00002512-199608030-00006","volume":"8","author":"S Noble","year":"1996","unstructured":"Noble S, Goa KL (1996) Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Drugs Aging 8: 214\u2013232","journal-title":"Drugs Aging"},{"key":"330_CR63","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"ME Bertrand","year":"2000","unstructured":"Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH (2000) Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102: 624\u2013629","journal-title":"Circulation"},{"key":"330_CR64","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494\u2013502","journal-title":"N Engl J Med"},{"key":"330_CR65","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA (2001) Effects of pretreatment with clopidogrel and aspirin followed by longterm therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358: 527\u2013533","journal-title":"Lancet"},{"key":"330_CR66","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cardfail.2004.02.006","volume":"10","author":"BM Massie","year":"2004","unstructured":"Massie BM, Krol WF, Ammon SE, Armstrong PW, Cleland JG, Collins JF, Ezekowitz M, Jafri SM, O'Connor CM, Packer M, Schulman KA, Teo K, Warren S (2004) The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 10: 101\u2013112","journal-title":"J Card Fail"},{"key":"330_CR67","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ (2006) Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med 354: 1706\u20131717","journal-title":"N Engl J Med"},{"key":"330_CR68","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352: 1179\u20131189","journal-title":"N Engl J Med"},{"key":"330_CR69","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1021\/jm981072s","volume":"42","author":"AH Ingall","year":"1999","unstructured":"Ingall AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, Hunt SF, Kindon ND, Teobald BJ, Willis PA, Humphries RG, Leff P, Clegg JA, Smith JA, Tomlinson W (1999) Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 42: 213\u2013220","journal-title":"J Med Chem"},{"key":"330_CR70","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/09537100120085450","volume":"12","author":"RF Storey","year":"2001","unstructured":"Storey RF, Newby LJ, Heptinstall S (2001) Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 12: 443\u2013447","journal-title":"Platelets"},{"key":"330_CR71","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0037-1615596","volume":"85","author":"RF Storey","year":"2001","unstructured":"Storey RF, Oldroyd KG, Wilcox RG (2001) Open multicentre study of the P2T receptor antagonist ARC69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 85: 401\u2013407","journal-title":"Thromb Haemost"},{"key":"330_CR72","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1055\/s-0037-1613242","volume":"88","author":"RF Storey","year":"2002","unstructured":"Storey RF, Judge HM, Wilcox RG, Heptinstall S (2002) Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 88: 488\u2013494","journal-title":"Thromb Haemost"},{"key":"330_CR73","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1161\/CIRCULATIONAHA.104.502815","volume":"111","author":"SD Wiviott","year":"2005","unstructured":"Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E (2005) Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111: 3366\u20133373","journal-title":"Circulation"},{"key":"330_CR74","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/09537100410001682788","volume":"15","author":"MP Mahaut-Smith","year":"2004","unstructured":"Mahaut-Smith MP, Tolhurst G, Evans RJ (2004) Emerging roles for P2X1 receptors in platelet activation. Platelets 15: 131\u2013144","journal-title":"Platelets"},{"key":"330_CR75","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1182\/blood-2002-10-3215","volume":"101","author":"C Oury","year":"2003","unstructured":"Oury C, Kuijpers MJ, Toth-Zsamboki E, Bonnefoy A, Danloy S, Vreys I, Feijge MA, De Vos R, Vermylen J, Heemskerk JW, Hoylaerts MF (2003) Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood 101: 3969\u20133976","journal-title":"Blood"},{"key":"330_CR76","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-0038-1642662","volume":"74","author":"KJ Clemetson","year":"1995","unstructured":"Clemetson KJ (1995) Platelet activation: signal transduction via membrane receptors. Thromb Haemost 74: 111\u2013116","journal-title":"Thromb Haemost"},{"key":"330_CR77","first-page":"57","volume":"100","author":"BS Coller","year":"1997","unstructured":"Coller BS (1997) Platelet GPIIb\/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 100: 57\u201360","journal-title":"J Clin Invest"},{"key":"330_CR78","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/pgmj.2003.007062","volume":"80","author":"MW Behan","year":"2004","unstructured":"Behan MW, Storey RF (2004) Antiplatelet therapy in cardiovascular disease. Postgrad Med J 80: 155\u2013164","journal-title":"Postgrad Med J"},{"key":"330_CR79","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1067\/mcp.2002.121775","volume":"71","author":"DR Abernethy","year":"2002","unstructured":"Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J (2002) Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects. Clin Pharmacol Ther 71: 186\u2013195","journal-title":"Clin Pharmacol Ther"},{"key":"330_CR80","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa031859","volume":"350","author":"A Kastrati","year":"2004","unstructured":"Kastrati A, Mehilli J, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schomig A (2004) A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350: 232\u2013238","journal-title":"N Engl J Med"},{"key":"330_CR81","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/eurheartj\/ehi174","volume":"26","author":"A Schomig","year":"2005","unstructured":"Schomig A, Schmitt C, Dibra A, Mehilli J, Volmer C, Schuhlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Berger PB, Kastrati A (2005) One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J 26: 1379\u20131384","journal-title":"Eur Heart J"},{"key":"330_CR82","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","volume":"330","author":"The EPIC investigators","year":"1994","unstructured":"The EPIC investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 330: 956\u2013961","journal-title":"N Engl J Med"},{"key":"330_CR83","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","volume":"336","author":"The EPILOG Investigators","year":"1997","unstructured":"The EPILOG Investigators (1997) Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336: 1689\u20131696","journal-title":"N Engl J Med"},{"key":"330_CR84","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(99)10018-7","volume":"354","author":"EJ Topol","year":"1999","unstructured":"Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RM (1999) Outcomes at 1 year and economic implications of platelet glycoprotein IIb\/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting. Lancet 354: 2019\u20132024","journal-title":"Lancet"},{"key":"330_CR85","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","volume":"356","author":"The ESPRIT investigators","year":"2000","unstructured":"The ESPRIT investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356: 2037\u20132044","journal-title":"Lancet"},{"key":"330_CR86","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/01.CIR.101.7.751","volume":"101","author":"NS Kleiman","year":"2000","unstructured":"Kleiman NS, Lincoff AM, Flaker GC, Pieper KS, Wilcox RG, Berdan LG, Lorenz TJ, Cokkinos DV, Simoons ML, Boersma E, Topol EJ, Califf RM, Harrington RA (2000) Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. Circulation 101: 751\u2013757","journal-title":"Circulation"},{"key":"330_CR87","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","volume":"295","author":"A Kastrati","year":"2006","unstructured":"Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schomig A, Schmitt C, Dibra A, Volmer C, ten Berg JM (2006) Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. JAMA 295: 1531\u20131538","journal-title":"JAMA"},{"key":"330_CR88","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.CIR.98.8.734","volume":"98","author":"SJ Brener","year":"1998","unstructured":"Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ (1998) Randomized, placebo-controlled trial of platelet glycoprotein IIb\/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98: 734\u2013741","journal-title":"Circulation"},{"key":"330_CR89","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0735-1097(99)00635-X","volume":"35","author":"FJ Neumann","year":"2000","unstructured":"Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M, Schleef M, Seyfarth M, Dirschinger J, Schomig A (2000) Effect of glycoprotein IIb\/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 35: 915\u2013921","journal-title":"J Am Coll Cardiol"},{"key":"330_CR90","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","volume":"344","author":"G Montalescot","year":"2001","unstructured":"Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P (2001) Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344: 1895\u20131903","journal-title":"N Engl J Med"},{"key":"330_CR91","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMoa013404","volume":"346","author":"GW Stone","year":"2002","unstructured":"Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346: 957\u2013966","journal-title":"N Engl J Med"},{"key":"330_CR92","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.jacc.2003.09.010","volume":"42","author":"EJ Topol","year":"2003","unstructured":"Topol EJ, Neumann FJ, Montalescot G (2003) A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 42: 1886\u20131889","journal-title":"J Am Coll Cardiol"},{"key":"330_CR93","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jacc.2003.07.017","volume":"42","author":"D Antoniucci","year":"2003","unstructured":"Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, Parodi G, Fernandez-Pereira C, Moschi G, Bartorelli A, Santoro GM, Bolognese L, Colombo A (2003) A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 42: 1879\u20131885","journal-title":"J Am Coll Cardiol"},{"key":"330_CR94","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jama.293.14.1759","volume":"293","author":"G De Luca","year":"2005","unstructured":"De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ (2005) Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293: 1759\u20131765","journal-title":"JAMA"},{"issue":"2","key":"330_CR95","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.102.2.149","volume":"102","author":"CP Cannon","year":"2000","unstructured":"Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E (2000) Oral glycoprotein IIb\/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 102(2): 149\u2013156","journal-title":"Circulation"},{"key":"330_CR96","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0140-6736(99)11179-6","volume":"355","author":"The SYMPHONY Investigators","year":"2000","unstructured":"The SYMPHONY Investigators (2000) Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Lancet 355: 337\u2013345","journal-title":"Lancet"},{"key":"330_CR97","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1161\/01.CIR.103.13.1727","volume":"103","author":"Second SYMPHONY investigators","year":"2001","unstructured":"Second SYMPHONY investigators (2001) Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 103: 1727\u20131733","journal-title":"Circulation"},{"key":"330_CR98","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM200005043421803","volume":"342","author":"WW O'Neill","year":"2000","unstructured":"O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwaan C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R (2000) Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 342: 1316\u20131324","journal-title":"N Engl J Med"},{"key":"330_CR99","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1067\/mhj.2000.105107","volume":"139","author":"EJ Topol","year":"2000","unstructured":"Topol EJ, Easton JD, Amarenco P, Califf R, Harrington R, Graffagnino C, Davis S, Diener HC, Ferguson J, Fitzgerald D, Shuaib A, Koudstaal PJ, Theroux P, Van de Werf F, Willerson JT, Chan R, Samuels R, Ilson B, Granett J (2000) Design of the blockade of the glycoprotein IIb\/IIIa receptor to avoid vascular occlusion (BRAVO) trial. Am Heart J 139: 927\u2013933","journal-title":"Am Heart J"},{"key":"330_CR100","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.103.2.201","volume":"103","author":"DP Chew","year":"2001","unstructured":"Chew DP, Bhatt DL, Sapp S, Topol EJ (2001) Increased mortality with oral platelet glycoprotein IIb\/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103: 201\u2013206","journal-title":"Circulation"},{"key":"330_CR101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1527-3466.2001.tb00181.x","volume":"19","author":"K Baba","year":"2001","unstructured":"Baba K, Aga Y, Nakanishi T, Motoyama T, Ueno H (2001) UR-3216: a manageable oral GPIIb\/IIIa antagonist. Cardiovasc Drug Rev 19: 25\u201340","journal-title":"Cardiovasc Drug Rev"},{"key":"330_CR102","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2174\/1381612043384592","volume":"10","author":"Y Aga","year":"2004","unstructured":"Aga Y, Baba K, Tam S, Nakanishi T, Yoneda K, Kita J, Ueno H (2004) UR-3216: a new generation oral platelet GPIIb\/IIIa antagonist. Curr Pharm Des 10: 1597\u20131601","journal-title":"Curr Pharm Des"},{"key":"330_CR103","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00129784-200303020-00004","volume":"3","author":"J Murphy","year":"2003","unstructured":"Murphy J, Wright RS, Gussak I, Williams B, Daly RN, Cain VA, Pieniaszek HJ, Sy SK, Ebling W, Simonson K, Wilcox RA, Kopecky SL (2003) The Use of Roxifiban (DMP754), a novel oral platelet glycoprotein IIb\/IIIa receptor inhibitor, in patients with stable coronary artery disease. Am J Cardiovasc Drugs 3: 101\u2013112","journal-title":"Am J Cardiovasc Drugs"},{"key":"330_CR104","doi-asserted-by":"crossref","unstructured":"Serebruany VL, Malinin AI, O'Connor C M, Gurbel PA. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). Am Heart J 146: 91\u201398","DOI":"10.1016\/S0002-8703(03)00186-8"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-006-0330-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-006-0330-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-006-0330-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T17:27:45Z","timestamp":1587230865000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-006-0330-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":104,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["330"],"URL":"https:\/\/doi.org\/10.1007\/s10354-006-0330-5","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}